Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

10 Background: The TheraP trial showed that LuPSMA improved PSA≥50% response rate (PSA50-RR), PSA-PFS, and radiographic PFS (rPFS) compared with cabazitaxel in mCRPC progressing after docetaxel. Study inclusion required high PSMA uptake (SUVmax≥20) and no lesions that were FDG+ and PSMA-. Here we report on PSMA PET and FDG PET as potential predictive and prognostic biomarkers. Methods: We...

  • 123456 Profile photo of Madelyn

    Higher SUV predictive of higher likelihood of favorable response to Lu-PSMA